These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22744936)

  • 1. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint.
    Brückner M; Titman A; Jaki T
    Stat Med; 2017 Sep; 36(20):3137-3153. PubMed ID: 28612371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints.
    Di Stefano F; Pannaux M; Correges A; Galtier S; Robert V; Saint-Hilary G
    Stat Med; 2022 May; 41(10):1767-1779. PubMed ID: 35098579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach.
    Bowden J; Brannath W; Glimm E
    Stat Med; 2014 Feb; 33(3):388-400. PubMed ID: 23873666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision of maximum likelihood estimation in adaptive designs.
    Graf AC; Gutjahr G; Brannath W
    Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modest proposal for dropping poor arms in clinical trials.
    Proschan MA; Dodd LE
    Stat Med; 2014 Aug; 33(19):3241-52. PubMed ID: 24757049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unbiased estimation for response adaptive clinical trials.
    Bowden J; Trippa L
    Stat Methods Med Res; 2017 Oct; 26(5):2376-2388. PubMed ID: 26265771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shrinkage estimation of effect sizes as an alternative to hypothesis testing followed by estimation in high-dimensional biology: applications to differential gene expression.
    Montazeri Z; Yanofsky CM; Bickel DR
    Stat Appl Genet Mol Biol; 2010; 9():Article23. PubMed ID: 20597849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point estimation following a two-stage group sequential trial.
    Grayling MJ; Wason JM
    Stat Methods Med Res; 2023 Feb; 32(2):287-304. PubMed ID: 36384365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusting for treatment selection in phase II/III clinical trials with time to event data.
    Khan JN; Kimani PK; Glimm E; Stallard N
    Stat Med; 2023 Jan; 42(2):146-163. PubMed ID: 36419206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference on P(X < Y) in Bivariate Lomax model based on progressive type II censoring.
    Helu A; Samawi H
    PLoS One; 2022; 17(5):e0267981. PubMed ID: 35551550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulation-based adjustment after exploratory biomarker subgroup selection in phase II.
    Götte H; Kirchner M; Sailer MO; Kieser M
    Stat Med; 2017 Jul; 36(15):2378-2390. PubMed ID: 28436046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.